Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.
Fatema AlrashedHajer AlasfourMohammad ShehabPublished in: JGH open : an open access journal of gastroenterology and hepatology (2022)
Regarding COVID-19-related hospitalization in IBD, anti-TNFs and ustekinumab were associated with decreased risk of hospitalization. In addition, vedolizumab and tofacitinib were not associated with COVID-19-related hospitalization.